Apheresis equipment market will exceed USD 4.5 billion by 2025; as per a new research report.

Favorable regulatory scenario for apheresis in developed countries is projected to drive the demand for pheresis equipment. The European Commission has emboldened several initiatives to ensure safety and quality associated with distribution, storage, processing and collection of blood components. Various initiatives to encourage growing need of plasma and blood components for individuals requiring derived blood products and plasma transfusions for survival, will boost the demand for apheresis equipment. Additionally, Article 110 of Directive 2001/83/EC encourages the manufacturers to produce blood derived or human plasma derived medicinal products for use in the treatment of blood related disorders. Hence, the above mentioned aspects will prove beneficial for the apheresis devices industry growth.

Increasing occurrence of blood disorders is a foremost factor stimulating the apheresis equipment market growth worldwide. It disturbs the blood clotting ability of an individual and can affect any age group including infant, adult and elderly population base. Moreover, population susceptible to various blood related disorders including hemophilia A, B, thalassemia, sickle-cell disease and blood cancers, leads to an increase in the demand for blood components, further accelerating the business growth. However, short shelf life of blood components may impede the apheresis equipment industry growth to certain extent over the coming years.

Apheresis machines segment accounted for over 30% revenue share in 2018 and should show considerable growth during the forecast period. Segment growth is attributed to growing demand for apheresis machines owing to its durability and extensively use in the transfusion treatment. In addition, availability of higher class of machines for efficient separation of various blood and plasma components will further favor segment growth.

Hematology segment was valued around 795 million in 2018. The (HAU) hematology apheresis unit is preferably used to measure blood components and marrow that have stem cell peripheral blood assemblies. Increasing usage of these devices in hematology for specific examination and analysis, should upsurge apheresis devices industry growth.

Plasmapheresis segment is estimated to exceed USD 2.2 billion by 2025. Plasmapheresis is an extracorporeal technique of blood purification that involves removal of plasma from patient?s blood. Surge in adoption of this technique in the treatment of autoimmune diseases for replacing components with appropriate intravenous fluid will boost segment growth during the forecast timeframe.

Membrane filtration segment held significant share in 2018 and is poised to show over 10% CAGR over the analysis period. Rising demand for platelets and plasma in the treatment of several blood related disorders will stimulate the segment growth. Furthermore, advantages such as effective functioning and flexibility at low temperatures will foster the membrane filtration segment growth.

North America apheresis equipment industry accounted for more than 40.0% revenue share in 2018 and is projected to witness momentous CAGR by 2025. Availability of advanced healthcare infrastructure along with increasing healthcare concerns among the population will propel the regional business growth. Moreover, relatively high healthcare spending in the region should further augment the industry growth.

Few prominent business players operating in apheresis equipment market include Haemonetics, Terumo BCT, Fenwal, Kawasumi Laboratories B. Braun, Asahi Kasei Kuraray Medical, Therakos, Hemacare, and Fresenius. The business players focus on various inorganic strategies to maintain their financial stability and sustain market competition. For instance, in April 2017, B. Braun partnered with Christie Medical Holdings, Inc. with an aim to improve peripheral IV access success and enhance patient care.